Online Resource 1 Antialdosterone in Acute Myocardial Infarction patients: a Meta-Analysis and Systematic Review Cardiovascular Drugs and Therapy Qiao Chen1*, Zhuqing Li 2, Die Zhao 3, Jie Sun 4, Yiling Wang 5, Yanxin Wang 6, Xuemei Yin 7, Jiaxin Feng 8, Chengzhi Lu 9 * The corresponding author Department of Cardiology, Tianjin First Center Hospital, Tianjin Medical University. No. 24 Fukang Road, Nankai District, Tianjin, China. [email protected] Search strategies in details for the meta-analysis Pubmed (Mineralocorticoid Receptor Antagonists or MRAs or mineralocorticoid antagonist or aldosterone receptor antagonist or aldosterone receptor blockade or aldosterone receptor blocker or aldosterone receptor blocking agents or aldosterone blockade or aldosterone antagonist or antialdosterone or canrenoate or potassium canrenoate or canrenone or canrenoic acid or spironolactone or aldactone or eplerenone or ispra) AND (cardiovascular diseases or heart diseases or coronary artery diseases or acute coronary syndrome or ACS or myocardial infarction or MI or acute myocardial infarction or AMI) AND ([clinical trial]/lim or [randomized controlled trial]/lim) Embase ('Mineralocorticoid Receptor Antagonists' or 'mineralocorticoid antagonist' or 'aldosterone receptor antagonist' or 'aldosterone receptor blockade' or 'aldosterone receptor blocker' or 'aldosterone receptor blocking agents' or 'aldosterone blockade' or 'aldosterone antagonist' or 'antialdosterone' or 'canrenoate' or 'potassium canrenoate' or 'canrenone' or 'canrenoic acid' or 'spironolactone' or 'aldactone' or 'eplerenone' or 'ispra') AND ('cardiovascular diseases' or 'heart diseases' or 'coronary artery diseases' or 'acute coronary syndrome' or 'myocardial infarction' or 'acute myocardial infarction') AND ([clinical trial]/lim or [randomized controlled trial]/lim AND [humans]/lim Cochrane library (Mineralocorticoid Receptor Antagonists or MRAs or mineralocorticoid antagonist or aldosterone receptor antagonist or aldosterone receptor blockade or aldosterone receptor blocker or aldosterone receptor blocking agents or aldosterone blockade or aldosterone antagonist or antialdosterone or canrenoate or potassium canrenoate or canrenone or canrenoic acid or spironolactone or aldactone or eplerenone or ispra) AND (cardiovascular diseases or heart diseases or coronary artery diseases or acute coronary syndrome or ACS or myocardial infarction or MI or acute myocardial infarction or AMI) AND (RCT OR randomi$ez controlled trial* OR clinical trial*) Ovid (MEDLINE 1946 to 2021) (Mineralocorticoid Receptor Antagonists or MRAs or mineralocorticoid antagonist or aldosterone receptor antagonist or aldosterone receptor blockade or aldosterone receptor blocker or aldosterone receptor blocking agents or aldosterone blockade or aldosterone antagonist or antialdosterone or canrenoate or potassium canrenoate or canrenone or canrenoic acid or spironolactone or aldactone or eplerenone or ispra) AND (cardiovascular diseases or heart diseases or coronary artery diseases or acute coronary syndrome or ACS or myocardial infarction or MI or acute myocardial infarction or AMI) AND ([clinical trial]/lim or [randomized controlled trial]/lim) AND [humans]/lim AND [english language]/lim AND [full text]/lim clinicaltrials.gov (aldosterone receptor antagonist or aldosterone receptor blockade or aldosterone receptor blocker or aldosterone receptor blocking agents or canrenoate or potassium canrenoate or canrenone or canrenoic acid or spironolactone or eplerenone or rn 52-01-7 or rn 107724-20-9 or aldactone or ispra) AND (myocardial infarction) .